Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 19 May 2022
EMA accepts filing of marketing authorisation application for Valneva’s inactivated COVID-19 vaccine candidate
19 May 2022 - 2022 – Valneva today confirmed that the EMA has accepted the filing of a marketing authorisation ...
Posted by Michael Wonder on 19 May 2022
Multiple funding proposals being considered by PHARMAC
19 May 2022 - PHARMAC has issued three consultations today on proposals to fund medicines for conditions including cancer, multiple sclerosis, ...
Posted by Michael Wonder on 19 May 2022
COVID-19 vaccine weekly safety report (19 May 2022)
19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 May 2022
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread
17 May 2022 - A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the ...
Posted by Michael Wonder on 19 May 2022
PHARMAC will use biggest budget increase ever to fund more medicines for more New Zealanders
19 May 2022 - PHARMAC welcomes the $191 million increase to its pharmaceutical budget over the next two years. ...
Posted by Michael Wonder on 18 May 2022
CMS unveils more user friendly Medicare website
18 May 2022 - New Medicare.gov will incorporate public feedback and make it easier to compare, choose, and understand Medicare ...
Posted by Michael Wonder on 18 May 2022
Alnylam announces Health Canada authorisation of Oxlumo (lumasiran), the first and only treatment for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients
18 May 2022 - Authorization based on two pivotal Phase 3 trials, ILLUMINATE-A and ILLUMINATE-B; showing significant reduction in urinary ...
Posted by Michael Wonder on 18 May 2022
Toward incorporating health-related quality of life as co-primary endpoints in clinical trials: time to achieve clinical important differences and quality of life profiles
16 May 2022 - Besides morbidity and mortality, quality of life is a key outcome of cancer treatments. ...
Posted by Michael Wonder on 18 May 2022
Budget 2022: two year old girl and mum travel to Wellington in hopes of getting funding for devastating spinal illness
19 May 2022 - Dozens of people are travelling to Wellington for the Budget to highlight concerns about sick children ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 18 May 2022
Cancer patient stares down the cost of buying time
18 May 2022 - It’s heartbreaking, frustrating, and it blows her mind. ...
Posted by Michael Wonder on 18 May 2022
FDA, EMA officials discuss impediments to cell and gene therapies
17 May 2022 - The US FDA's top biologics regulator said the use of a “playbook” or platform approach ...
Posted by Michael Wonder on 18 May 2022
Exactech announces FDA breakthrough device designation for JointMedica’s Polymotion hip resurfacing system
17 May 2022 - Exactech announced that the U.S. FDA has granted a breakthrough device designation for JointMedica’s Polymotion hip ...
Posted by Michael Wonder on 18 May 2022
VenoStent technology receives breakthrough device designation by FDA
17 May 2022 - Designation to promote more rapid agency and market access for VenoStent. ...
Posted by Michael Wonder on 17 May 2022
Understanding ‘evergreening’: making minor modifications of existing medications to extend protections
17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...